ThermoGenesis (THMO) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 12, 2021
Document Information [Line Items]
Entity Central Index Key	0000811212
Entity Registrant Name	ThermoGenesis Holdings, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	333-82900
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3018487
Entity Address, Address Line One	2711 Citrus Road
Entity Address, City or Town	Rancho Cordova
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95742
City Area Code	916
Local Phone Number	858-5100
Title of 12(b) Security	Common Stock, $.001 par value
Trading Symbol	THMO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		11,911,784

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 7,634,000	$ 7,161,000
Accounts receivable, net of allowance for doubtful accounts of $212,000 at September 30, 2021 ($214,000 at December 31, 2020)	2,571,000	1,382,000
Inventories	5,538,000	5,877,000
Prepaid expenses and other current assets	1,138,000	878,000
Total current assets	16,881,000	15,298,000
Inventories, non-current	1,784,000	1,221,000
Equipment and leasehold improvements, net	1,339,000	1,424,000
Right-of-use operating lease assets, net	614,000	730,000
Goodwill	781,000	781,000
Other intangible assets, net	1,326,000	1,358,000
Other assets	48,000	48,000
Total assets	22,773,000	20,860,000
Current liabilities:
Accounts payable	1,502,000	1,366,000
Accrued payroll and related expenses	461,000	349,000
Deferred revenue – short-term	943,000	608,000
Convertible promissory note – related party, net	8,417,000
Interest payable – related party	1,668,000	2,082,000
Note payable – short-term		447,000
Convertible promissory note, net	733,000
Other current liabilities	1,011,000	1,291,000
Total current liabilities	14,735,000	6,143,000
Convertible promissory note – related party, net		5,935,000
Convertible promissory note, net		493,000
Note payable		199,000
Operating lease obligations – long-term	455,000	604,000
Deferred revenue – long-term	1,395,000	1,596,000
Other noncurrent liabilities	20,000	20,000
Total liabilities	16,605,000	14,990,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding	0	0
Common stock, $0.001 par value; 350,000,000 shares authorized; 11,911,784 issued and outstanding (8,934,952 at December 31, 2020)	12,000	9,000
Additional paid in capital	268,336,000	259,058,000
Accumulated deficit	(262,009,000)	(253,283,000)
Accumulated other comprehensive loss	28,000	16,000
Total ThermoGenesis Holdings, Inc. stockholders’ equity	6,367,000	5,800,000
Noncontrolling interests	(199,000)	70,000
Total equity	6,168,000	5,870,000
Total liabilities and equity	$ 22,773,000	$ 20,860,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accounts receivable, allowance for doubtful accounts	$ 212,000	$ 214,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	11,911,784	8,934,952
Common stock, shares outstanding (in shares)	11,911,784	8,934,952

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net revenues	$ 3,158,000	$ 2,355,000	$ 6,876,000	$ 7,797,000
Cost of revenues	2,043,000	844,000	4,067,000	7,426,000
Gross profit (loss)	1,115,000	1,511,000	2,809,000	371,000
Expenses:
Selling, general and administrative	1,677,000	1,844,000	7,171,000	5,913,000
Research and development	543,000	750,000	1,544,000	1,937,000
Total operating expenses	2,220,000	2,594,000	8,715,000	7,850,000
Loss from operations	(1,105,000)	(1,083,000)	(5,906,000)	(7,479,000)
Other expenses:
Interest expense	(1,530,000)	(1,531,000)	(4,573,000)	(6,377,000)
Gain/(loss) on extinguishment of debt			652,000
Other income/(expense)	843,000	5,000	833,000	(6,000)
Total other expense	(687,000)	(1,526,000)	(3,088,000)	(6,383,000)
Net loss	(1,792,000)	(2,609,000)	(8,994,000)	(13,862,000)
Loss attributable to noncontrolling interests	(18,000)	(146,000)	(269,000)	(360,000)
Net loss attributable to common stockholders	(1,774,000)	(2,463,000)	(8,725,000)	(13,502,000)
Net loss	(1,792,000)	(2,609,000)	(8,994,000)	(13,862,000)
Other comprehensive loss:
Foreign currency translation adjustments gain (loss)	(1,000)	(19,000)	12,000	20,000
Comprehensive loss	(1,793,000)	(2,628,000)	(8,982,000)	(13,842,000)
Comprehensive loss attributable to noncontrolling interests	(18,000)	(146,000)	(269,000)	(360,000)
Comprehensive loss attributable to common stockholders	$ (1,775,000)	$ (2,482,000)	$ (8,713,000)	$ (13,482,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.15)	$ (0.37)	$ (0.74)	$ (2.36)
Weighted average common shares outstanding – basic and diluted (in shares)	11,911,784	6,711,664	11,757,211	5,728,105

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Equity (Unaudited) - USD ($)	At The Market Offering Agreement [Member]Common Stock [Member]	At The Market Offering Agreement [Member]Additional Paid-in Capital [Member]	At The Market Offering Agreement [Member]	Boyalife Asset Holding II [Member]Common Stock [Member]	Boyalife Asset Holding II [Member]Additional Paid-in Capital [Member]	Boyalife Asset Holding II [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]		Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2019							2,843,601
Balance at Dec. 31, 2019							$ 3,000	$ 237,313,000	$ (236,932,000)	$ 2,000	[1]	$ 530,000	$ 916,000
Stock-based compensation expense								67,000					67,000
Issuance of common stock (in shares)							1,050,748
Issuance of common stock							$ 1,000	3,220,000					3,221,000
Foreign currency translation gain (loss)										38,000	[1]		38,000
Net loss									(4,602,000)			(141,000)	(4,743,000)
Exercise of pre-funded warrants (in shares)							100,000
Exercise of pre-funded warrants								10,000					10,000
Exercise of warrants (in shares)							7,866
Exercise of warrants								47,000					47,000
Discount due to beneficial conversion features								1,869,000					1,869,000
Conversion of note payable to common stock (in shares)				1,666,670			100,000
Conversion of related party note payable to common stock				$ 2,000	$ 2,998,000	$ 3,000,000		180,000					180,000
Balance (in shares) at Mar. 31, 2020							5,768,885
Balance at Mar. 31, 2020							$ 6,000	245,704,000	(241,534,000)	40,000	[1]	389,000	4,605,000
Balance (in shares) at Dec. 31, 2019							2,843,601
Balance at Dec. 31, 2019							$ 3,000	237,313,000	(236,932,000)	2,000	[1]	530,000	916,000
Foreign currency translation gain (loss)													20,000
Balance (in shares) at Sep. 30, 2020							6,832,040
Balance at Sep. 30, 2020							$ 7,000	253,537,000	(250,434,000)	22,000		170,000	3,302,000
Balance (in shares) at Mar. 31, 2020							5,768,885
Balance at Mar. 31, 2020							$ 6,000	245,704,000	(241,534,000)	40,000	[1]	389,000	4,605,000
Stock-based compensation expense								314,000					314,000
Issuance of common stock (in shares)							344,419
Issuance of common stock								1,993,000					1,993,000
Foreign currency translation gain (loss)										1,000			1,000
Net loss									(6,437,000)			(73,000)	(6,510,000)
Exercise of pre-funded warrants (in shares)							224,445
Exercise of pre-funded warrants								22,000					22,000
Exercise of warrants (in shares)							267,271
Exercise of warrants								1,604,000					1,604,000
Discount due to beneficial conversion features								3,112,000					3,112,000
Conversion of note payable to common stock (in shares)							104,445
Conversion of related party note payable to common stock							$ 1,000	188,000					189,000
Balance (in shares) at Jun. 30, 2020							6,709,465
Balance at Jun. 30, 2020							$ 7,000	252,937,000	(247,971,000)	41,000	[1]	316,000	5,330,000
Stock-based compensation expense								234,000					234,000
Issuance of common stock (in shares)							122,575
Issuance of common stock								366,000					366,000
Foreign currency translation gain (loss)										(19,000)			(19,000)
Net loss									(2,463,000)			(146,000)	(2,609,000)
Balance (in shares) at Sep. 30, 2020							6,832,040
Balance at Sep. 30, 2020							$ 7,000	253,537,000	(250,434,000)	22,000		170,000	3,302,000
Balance (in shares) at Dec. 31, 2020							8,934,952
Balance at Dec. 31, 2020							$ 9,000	259,058,000	(253,283,000)	16,000	[1]	70,000	5,870,000
Stock-based compensation expense								258,000					258,000
Issuance of common stock (in shares)	2,976,832
Issuance of common stock	$ 3,000	$ 6,829,000	$ 6,832,000
Foreign currency translation gain (loss)										1,000	[1]		1,000
Net loss									(2,413,000)			(118,000)	(2,531,000)
Balance (in shares) at Mar. 31, 2021							11,911,784
Balance at Mar. 31, 2021							$ 12,000	266,145,000	(255,696,000)	17,000	[1]	(48,000)	10,430,000
Balance (in shares) at Dec. 31, 2020							8,934,952
Balance at Dec. 31, 2020							$ 9,000	259,058,000	(253,283,000)	16,000	[1]	70,000	5,870,000
Issuance of common stock (in shares)			2,976,832
Foreign currency translation gain (loss)													12,000
Balance (in shares) at Sep. 30, 2021							11,911,784
Balance at Sep. 30, 2021							$ 12,000	268,336,000	(262,009,000)	28,000		(199,000)	6,168,000
Balance (in shares) at Mar. 31, 2021							11,911,784
Balance at Mar. 31, 2021							$ 12,000	266,145,000	(255,696,000)	17,000	[1]	(48,000)	10,430,000
Stock-based compensation expense								2,099,000					2,099,000
Foreign currency translation gain (loss)										12,000			12,000
Net loss									(4,539,000)			(133,000)	(4,672,000)
Balance (in shares) at Jun. 30, 2021							11,911,784
Balance at Jun. 30, 2021							$ 12,000	268,244,000	(260,235,000)	29,000	[1]	(181,000)	7,869,000
Stock-based compensation expense								92,000					92,000
Foreign currency translation gain (loss)										(1,000)			(1,000)
Net loss									(1,774,000)			(18,000)	(1,792,000)
Balance (in shares) at Sep. 30, 2021							11,911,784
Balance at Sep. 30, 2021							$ 12,000	$ 268,336,000	$ (262,009,000)	$ 28,000		$ (199,000)	$ 6,168,000
[1]	Accumulated other comprehensive loss.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (8,994,000)	$ (13,862,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	477,000	569,000
Stock based compensation expense	2,449,000	615,000
Amortization of debt discount/premium, net	2,723,000	2,165,000
Amortization of accelerated debt discount due to conversion		2,486,000
Reserve for excess and slow-moving inventories	336,000	4,036,000
Reserve for bad debt expense		(6,000)
Loss on disposal of equipment		118,000
Gain on extinguishment of debt	(652,000)
Net change in operating assets and liabilities:
Accounts receivable	(1,190,000)	(414,000)
Inventories	(742,000)	(6,086,000)
Prepaid expenses and other assets	(260,000)	6,000
Accounts payable	145,000	223,000
Interest payable - related party	(413,000)	(350,000)
Accrued payroll and related expenses	111,000	225,000
Deferred revenue – short-term	334,000	80,000
Other current liabilities	(271,000)	(1,326,000)
Long-term deferred revenue and other noncurrent liabilities	(347,000)	(338,000)
Net cash used in operating activities	(6,294,000)	(11,859,000)
Cash flows from investing activities:
Capital expenditures	(64,000)	(23,000)
Net cash used in investing activities	(64,000)	(23,000)
Cash flows from financing activities:
Proceeds from convertible promissory note-related party		4,287,000
Payments on financing lease obligations		(32,000)
Proceeds from issuance of common stock, net of expenses	6,832,000	5,580,000
Proceeds from exercise of options, warrants and pre-funded warrants		1,683,000
Proceeds from note payable		646,000
Net cash provided by financing activities	6,832,000	12,164,000
Effects of foreign currency rate changes on cash and cash equivalents	(1,000)	(3,000)
Net increase (decrease) in cash, cash equivalents and restricted cash	473,000	279,000
Cash, cash equivalents and restricted cash at beginning of period	7,161,000	4,157,000
Cash, cash equivalents and restricted cash at end of period	7,634,000	4,436,000
Supplemental disclosures of cash flow information:
Cash paid for interest	2,262,000	2,094,000
Supplemental non-cash financing and investing information:
Recording of beneficial conversion feature on debt		4,981,000
Transfer of inventory to fixed assets	$ 181,000
Conversion of Related Party Convertible Promissory Note Into Common Stock [Member]
Supplemental non-cash financing and investing information:
Related party promissory note converted to common stock		3,000,000
Conversion of January 2019 Amended Notes to Common Stock [Member]
Supplemental non-cash financing and investing information:
Related party promissory note converted to common stock		$ 369,000

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Description of Business ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”), develops, commercializes and markets a range of automated technologies for chimeric antigen receptor therapies (“CAR-T”) and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 The Company provides the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and CAR-TXpress™ platform for bio-manufacturing for immuno-oncology applications. The Company and its subsidiaries currently manufacture and market the following products: Clinical Bio-Banking Applications: ● AXP® 510 ● BioArchive® Automated Cryopreservation System – an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications, registered as a U.S. FDA 510 Point-of-Care Applications: ● PXP® 510 ● PXP-LAVARE System – an automated, fully closed system that is designed to wash, re-suspend and volume reduce cell suspensions. It allows for volume manipulation, supernatant or media exchange, and cell washing to occur without comprising cell viabilities and maximizing recoveries, registered as a U.S. FDA 510 ● PXP- 1000 510 Large Scale Cell Processing and Biomanufacturing: ● X X X X X ● CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing CAR-T cell therapies. The CAR-TXpress Platform is owned and developed through a subsidiary CAR-TXpress Bio, Inc. (“CARTXpress Bio”) in which the Company owns 80% of the equity interest. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10 8 X. Operating results for the three September 30, 2021 not may December 31, 2021. 10 December 31, 2020. Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings, Inc. and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. The 20% ownership interest of CARTXpress Bio that is not

Note 2 - Going Concern

Note 2 - Going Concern	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. GOING CONCERN At September 30, 2021, may may one The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The condensed consolidated financial statements do not may

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES There have been no 10 December 31, 2020. Recently Adopted Accounting Standards In December 2019, 2019 12 Income Taxes (Topic 740 2019 12 740 December 15, 2020. not nine September 30, 2021 not In January 2020, 2020 01, Investments Equity Securities (Topic 321 Equity Method and Joint Ventures (Topic 323 815 321, 323, 815 December 15, 2020, not Revenue Recognition Revenue is recognized based on the five 606. The following tables summarize the revenues by product line: Three Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,217,000 $ 72,000 $ 21,000 $ 2,310,000 BioArchive 221,000 297,000 -- 518,000 CAR-TXpress 160,000 31,000 71,000 262,000 Manual Disposables 55,000 -- -- 55,000 Other 9,000 -- 4,000 13,000 Total $ 2,662,000 $ 400,000 $ 96,000 $ 3,158,000 Nine Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 3,490,000 $ 159,000 $ 1,000 $ 3,670,000 BioArchive 652,000 1,165,000 -- 1,817,000 CAR-TXpress 702,000 89,000 214,000 1,005,000 Manual Disposables 300,000 -- -- 300,000 Other 46,000 -- 38,000 84,000 Total $ 5,190,000 $ 1,413,000 $ 273,000 $ 6,876,000 Three Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,137,000 $ 32,000 $ -- $ 1,169,000 BioArchive 337,000 282,000 -- 619,000 CAR-TXpress 332,000 22,000 71,000 425,000 Manual Disposables 100,000 -- -- 100,000 Other 26,000 -- 16,000 42,000 Total $ 1,932,000 $ 336,000 $ 87,000 $ 2,355,000 Nine Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,009,000 $ 103,000 $ -- $ 4,112,000 BioArchive 675,000 900,000 -- 1,575,000 CAR-TXpress 1,035,000 47,000 214,000 1,296,000 Manual Disposables 499,000 -- -- 499,000 Other 276,000 -- 39,000 315,000 Total $ 6,494,000 $ 1,050,000 $ 253,000 $ 7,797,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three nine September 30, 2021 nine September 30, 2021, Exclusivity Fee On August 30, 2019, five two two four X three nine September 30, 2021 2020, Distribution Agreement The Company signed a new agreement with its AXP distributor in China through 2023. 2021, two 2024. September 30, 2021, five per quarter September 30, 2021, Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2021 2022 2023 2024 2025 and beyond Total Service revenue $ 359,000 $ 962,000 $ 462,000 $ 189,000 $ 85,000 $ 2,057,000 Clinical revenue 3,000 13,000 13,000 13,000 160,000 202,000 Device revenue (1) 21,000 674,000 674,000 41,000 -- 1,410,000 Exclusivity fee 72,000 286,000 286,000 286,000 476,000 1,406,000 Total $ 455,000 $ 1,935,000 $ 1,435,000 $ 529,000 $ 721,000 $ 5,075,000 ( 1 Represents the minimum purchase requirements related to the Company AXP distributor in China Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not three nine September 30, 2021, one

Note 4 - Net Loss Per Share

Note 4 - Net Loss Per Share	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	4. NET LOSS PER SHARE Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no September 30: 2021 2020 Common stock equivalents of convertible promissory notes and accrued interest 7,071,241 6,988,334 Vested Series A warrants -- 40,441 Unvested Series A warrants (1) -- 69,853 Warrants – other 653,248 1,006,190 Stock options 366,595 892,149 Total 8,091,084 8,996,967 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.

Note 5 - Related Party Transact

Note 5 - Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	5. RELATED PARTY TRANSACTIONS HealthBanks Biotech (USA) Inc. On November 26, 2019 Between November 26, 2019 September 30, 2020, In March 2021, none no March 31, 2021. As of September 30, 2021, September 30, 2021, $750,000; Convertible Promissory Note and Revolving Credit Agreement In March 2017, March 6, 2022 ( September 30, 2021 December 31, 2020, The Credit Agreement and the Convertible Promissory Note issued thereunder (as amended, the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest. The Company has five January 2021, December 31, 2020 The Credit Agreement and Note were amended in April 2018, 2018, The following summarizes the Note: Maturity Date Stated Interest Rate Conversion Price Face Value Remaining Debt Discount Carrying Value At September 30, 2021 3/6/2022 22% $1.80 $10,000,000 $(1,583,000) $8,417,000 At December 31, 2020 3/6/2022 22% $1.80 $10,000,000 $(4,065,000) $5,935,000 The Company amortized $827,000 and $2,482,000 of debt discount to interest expense for the three nine September 30, 2021 three nine September 30 2020, three nine September 30, 2021 three nine September 30 2020, September 30, 2021 December 31, 2020

Note 6 - Convertible Promissory

Note 6 - Convertible Promissory Note	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	6. CONVERTIBLE PROMISSORY NOTE July 2019 On July 23, 2019, “July 2019 July 2019 July 2019 twenty-four July 2019 three July 31, 2022. The following summarizes the July 2019 Maturity Date Stated Interest Rate Conversion Price Face Value Remaining Debt Discount Carrying Value At September 30, 2021 7/31/2022 24% $1.80 $1,000,000 $(267,000) $733,000 At December 31, 2020 7/31/2022 24% $1.80 $1,000,000 $(507,000) $493,000 The Company recorded amortization expense for the debt discount on the July 2019 three nine September 30, 2021 three nine September 30, 2020. July 2019 three nine September 30, 2021 2020.

Note 7 - Leases

Note 7 - Leases	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7. LEASES The Company leases an approximately 28,000 first 2019 May 2024. Operating Leases Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not not The following summarizes the Company’s operating leases: September 30, 2021 December 31, 2020 Right-of-use operating lease assets, net $ 614,000 $ 730,000 Current lease liability (included in other current liabilities) 193,000 157,000 Non-current lease liability 455,000 604,000 Weighted average remaining lease term 2.7 3.4 Discount rate 22 % 22 % Maturities of lease liabilities by year for our operating leases are as follows: 2021 (Remaining) $ 78,000 2022 319,000 2023 328,000 2024 139,000 Total lease payments $ 864,000 Less: imputed interest (217,000 ) Present value of operating lease liabilities $ 647,000 Statement of Cash Flows In January 2019, three nine September 30, 2021 three nine September 30, 2020, Operating Lease Costs Operating lease costs were $107,000 and $316,000 for the three nine September 30, 2021 three nine September 30, 2020, Finance Leases Finance leases are included in equipment and other current and non-current liabilities on the condensed consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively on the statement of operations. These leases were not three nine September 30, 2021 2020.

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. COMMITMENTS AND CONTINGENCIES Contingencies In the normal course of operations, the Company may September 30, 2021, may not Financial Covenants On July 13, 2020, #2 July 13, 2020 ( May 15, 2017 #1 March 16, 2020 one September 30, 2021. Warranty The Company offers a warranty on all of its non-disposable products of one two The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the nine September 30, 2021 Balance at December 31, 2020 $ 154,000 Warranties issued during the period 53,000 Settlements made during the period (140,000 ) Changes in liability for pre-existing warranties during the period -- Balance at September 30, 2021 $ 67,000

Note 9 - Paycheck Protection Pr

Note 9 - Paycheck Protection Program	9 Months Ended
	Sep. 30, 2021
Paycheck Protection Program CARES Act [Member]
Notes to Financial Statements
Long-term Debt [Text Block]	9. PAYCHECK PROTECTION PROGRAM On April 21, 2020, two 1.00% first six may may December 2020, March 30, 2021 nine September 30, 2021,

Note 10 - Employee Retention Ta

Note 10 - Employee Retention Tax Credit	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Retirement Benefits [Text Block]	10. EMPLOYEE RETENTION TAX CREDIT Employee Retention Tax Credits (“ERTC”), created in the March 2020 2021 2021, 19 70% January 1, 2021 December 31, 2021. $10,000 2021 $7,000 The Company is eligible to receive the ERTC credits under the gross receipts decline test when comparing the first, second third 2021 2019, first three 2021 first three 2021, three nine September 30, 2021, September 30, 2021.

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	11. STOCKHOLDERS ’ EQUITY Common Stock On December 13, 2019, may May 19, 2020 September 30, 2021, nine September 30, 2021, Stock Based Compensation In May 2021, five June 2020. No three June 30, 2021. The Company recorded stock-based compensation of $92,000 and $2,449,000 for the three nine September 30, 2021, three nine September 30, 2020, Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenues $ 4,000 $ 3,000 $ 14,000 $ 5,000 Selling, general and administrative 64,000 195,000 2,194,000 538,000 Research and development 24,000 36,000 241,000 72,000 $ 92,000 $ 234,000 $ 2,449,000 $ 615,000 The following is a summary of option activity for the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2020 889,636 $ 8.57 8.7 $ -- Cancelled / Forfeited 523,041 Outstanding at September 30, 2021 366,595 $ 11.86 7.1 $ -- Vested and expected to vest at September 30, 2021 331,128 $ 12.36 6.9 $ -- Exercisable at September 30, 2021 244,245 $ 13.97 7.0 $ -- The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no options exercised during the nine September 30, 2021. Warrants A summary of warrant activity for the nine September 30, 2021 Number of Shares Weighted-Average Exercise Price Per Share Weighted- Average Remaining Contract Term Balance at December 31, 2020 1,116,484 $ 37.27 0.49 Warrants expired 463,236 Warrants exercised -- $ -- Outstanding at September 30, 2021 653,248 $ 6.97 1.70 Exercisable at September 30, 2021 653,248 $ 6.97 1.70

Note 12 - Major Customers and A

Note 12 - Major Customers and Accounts Receivable	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	12. MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE The Company had certain customers whose revenue individually represented 10% 10% For net revenues, one second third three September 30, 2021 2020, nine September 30, 2021 2020, one second third At September 30, 2021, December 31, 2020,

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards In December 2019, 2019 12 Income Taxes (Topic 740 2019 12 740 December 15, 2020. not nine September 30, 2021 not In January 2020, 2020 01, Investments Equity Securities (Topic 321 Equity Method and Joint Ventures (Topic 323 815 321, 323, 815 December 15, 2020, not
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue is recognized based on the five 606. The following tables summarize the revenues by product line: Three Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,217,000 $ 72,000 $ 21,000 $ 2,310,000 BioArchive 221,000 297,000 -- 518,000 CAR-TXpress 160,000 31,000 71,000 262,000 Manual Disposables 55,000 -- -- 55,000 Other 9,000 -- 4,000 13,000 Total $ 2,662,000 $ 400,000 $ 96,000 $ 3,158,000 Nine Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 3,490,000 $ 159,000 $ 1,000 $ 3,670,000 BioArchive 652,000 1,165,000 -- 1,817,000 CAR-TXpress 702,000 89,000 214,000 1,005,000 Manual Disposables 300,000 -- -- 300,000 Other 46,000 -- 38,000 84,000 Total $ 5,190,000 $ 1,413,000 $ 273,000 $ 6,876,000 Three Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,137,000 $ 32,000 $ -- $ 1,169,000 BioArchive 337,000 282,000 -- 619,000 CAR-TXpress 332,000 22,000 71,000 425,000 Manual Disposables 100,000 -- -- 100,000 Other 26,000 -- 16,000 42,000 Total $ 1,932,000 $ 336,000 $ 87,000 $ 2,355,000 Nine Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,009,000 $ 103,000 $ -- $ 4,112,000 BioArchive 675,000 900,000 -- 1,575,000 CAR-TXpress 1,035,000 47,000 214,000 1,296,000 Manual Disposables 499,000 -- -- 499,000 Other 276,000 -- 39,000 315,000 Total $ 6,494,000 $ 1,050,000 $ 253,000 $ 7,797,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three nine September 30, 2021 nine September 30, 2021, Exclusivity Fee On August 30, 2019, five two two four X three nine September 30, 2021 2020, Distribution Agreement The Company signed a new agreement with its AXP distributor in China through 2023. 2021, two 2024. September 30, 2021, five per quarter September 30, 2021, Backlog of Remaining Customer Performance Obligations The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period. Remainder of 2021 2022 2023 2024 2025 and beyond Total Service revenue $ 359,000 $ 962,000 $ 462,000 $ 189,000 $ 85,000 $ 2,057,000 Clinical revenue 3,000 13,000 13,000 13,000 160,000 202,000 Device revenue (1) 21,000 674,000 674,000 41,000 -- 1,410,000 Exclusivity fee 72,000 286,000 286,000 286,000 476,000 1,406,000 Total $ 455,000 $ 1,935,000 $ 1,435,000 $ 529,000 $ 721,000 $ 5,075,000 ( 1 Represents the minimum purchase requirements related to the Company AXP distributor in China Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not three nine September 30, 2021, one

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 2,217,000 $ 72,000 $ 21,000 $ 2,310,000 BioArchive 221,000 297,000 -- 518,000 CAR-TXpress 160,000 31,000 71,000 262,000 Manual Disposables 55,000 -- -- 55,000 Other 9,000 -- 4,000 13,000 Total $ 2,662,000 $ 400,000 $ 96,000 $ 3,158,000 Nine Months Ended September 30, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 3,490,000 $ 159,000 $ 1,000 $ 3,670,000 BioArchive 652,000 1,165,000 -- 1,817,000 CAR-TXpress 702,000 89,000 214,000 1,005,000 Manual Disposables 300,000 -- -- 300,000 Other 46,000 -- 38,000 84,000 Total $ 5,190,000 $ 1,413,000 $ 273,000 $ 6,876,000 Three Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,137,000 $ 32,000 $ -- $ 1,169,000 BioArchive 337,000 282,000 -- 619,000 CAR-TXpress 332,000 22,000 71,000 425,000 Manual Disposables 100,000 -- -- 100,000 Other 26,000 -- 16,000 42,000 Total $ 1,932,000 $ 336,000 $ 87,000 $ 2,355,000 Nine Months Ended September 30, 2020 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 4,009,000 $ 103,000 $ -- $ 4,112,000 BioArchive 675,000 900,000 -- 1,575,000 CAR-TXpress 1,035,000 47,000 214,000 1,296,000 Manual Disposables 499,000 -- -- 499,000 Other 276,000 -- 39,000 315,000 Total $ 6,494,000 $ 1,050,000 $ 253,000 $ 7,797,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Remainder of 2021 2022 2023 2024 2025 and beyond Total Service revenue $ 359,000 $ 962,000 $ 462,000 $ 189,000 $ 85,000 $ 2,057,000 Clinical revenue 3,000 13,000 13,000 13,000 160,000 202,000 Device revenue (1) 21,000 674,000 674,000 41,000 -- 1,410,000 Exclusivity fee 72,000 286,000 286,000 286,000 476,000 1,406,000 Total $ 455,000 $ 1,935,000 $ 1,435,000 $ 529,000 $ 721,000 $ 5,075,000

Note 4 - Net Loss Per Share (Ta

Note 4 - Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2021 2020 Common stock equivalents of convertible promissory notes and accrued interest 7,071,241 6,988,334 Vested Series A warrants -- 40,441 Unvested Series A warrants (1) -- 69,853 Warrants – other 653,248 1,006,190 Stock options 366,595 892,149 Total 8,091,084 8,996,967

Note 5 - Related Party Transa_2

Note 5 - Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	Maturity Date Stated Interest Rate Conversion Price Face Value Remaining Debt Discount Carrying Value At September 30, 2021 3/6/2022 22% $1.80 $10,000,000 $(1,583,000) $8,417,000 At December 31, 2020 3/6/2022 22% $1.80 $10,000,000 $(4,065,000) $5,935,000

Note 6 - Convertible Promisso_2

Note 6 - Convertible Promissory Note (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Convertible Debt [Table Text Block]	Maturity Date Stated Interest Rate Conversion Price Face Value Remaining Debt Discount Carrying Value At September 30, 2021 7/31/2022 24% $1.80 $1,000,000 $(267,000) $733,000 At December 31, 2020 7/31/2022 24% $1.80 $1,000,000 $(507,000) $493,000

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Lease, Cost [Table Text Block]	September 30, 2021 December 31, 2020 Right-of-use operating lease assets, net $ 614,000 $ 730,000 Current lease liability (included in other current liabilities) 193,000 157,000 Non-current lease liability 455,000 604,000 Weighted average remaining lease term 2.7 3.4 Discount rate 22 % 22 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2021 (Remaining) $ 78,000 2022 319,000 2023 328,000 2024 139,000 Total lease payments $ 864,000 Less: imputed interest (217,000 ) Present value of operating lease liabilities $ 647,000

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Balance at December 31, 2020 $ 154,000 Warranties issued during the period 53,000 Settlements made during the period (140,000 ) Changes in liability for pre-existing warranties during the period -- Balance at September 30, 2021 $ 67,000

Note 11 - Stockholders' Equity

Note 11 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenues $ 4,000 $ 3,000 $ 14,000 $ 5,000 Selling, general and administrative 64,000 195,000 2,194,000 538,000 Research and development 24,000 36,000 241,000 72,000 $ 92,000 $ 234,000 $ 2,449,000 $ 615,000
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2020 889,636 $ 8.57 8.7 $ -- Cancelled / Forfeited 523,041 Outstanding at September 30, 2021 366,595 $ 11.86 7.1 $ -- Vested and expected to vest at September 30, 2021 331,128 $ 12.36 6.9 $ -- Exercisable at September 30, 2021 244,245 $ 13.97 7.0 $ --
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Weighted-Average Exercise Price Per Share Weighted- Average Remaining Contract Term Balance at December 31, 2020 1,116,484 $ 37.27 0.49 Warrants expired 463,236 Warrants exercised -- $ -- Outstanding at September 30, 2021 653,248 $ 6.97 1.70 Exercisable at September 30, 2021 653,248 $ 6.97 1.70

Note 1 - Description of Busin_2

Note 1 - Description of Business and Basis of Presentation (Details Textual) - CAR-TXpress [Member]	Sep. 30, 2021
Noncontrolling Interest, Ownership Percentage by Parent	80.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	20.00%

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 7,634,000	$ 7,161,000
Working Capital	$ 2,146,000

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies (Details Textual)	Aug. 30, 2019USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Contract with Customer, Liability, Revenue Recognized		$ 118,000	$ 521,000
Contract with Customer, Liability, Current		943,000	943,000	$ 608,000
Contract with Customer, Liability, Noncurrent		1,395,000	1,395,000	$ 1,596,000
Exclusivity Fee [Member]
Contract with Customer, Liability, Revenue Recognized		71,000	214,000
Contract with Customer, Liability, Current		286,000	286,000
Contract with Customer, Liability, Noncurrent		1,119,000	1,119,000
Contract with Customer, Liability, Total	$ 2,000,000	1,405,000	1,405,000
Proceeds from Customers	$ 2,000,000
Supply Agreement [Member]
Supply Agreement, Term (Year)	5 years
Supply Agreement, Renewal Term, Number of Options	2
Supply Agreement, Renewal Term, Per Option (Year)	2 years
Supply Agreement [Member] | Maximum [Member]
Supply Agreement, Renewal Term (Year)	4 years
Distribution Agreement with AXP Distributor in China [Member]
Contract with Customer, Liability, Current		82,000	82,000
Contract with Customer, Liability, Noncurrent		27,000	27,000
Distributor Agreement, Minimum Purchase, Current Fiscal Year			1,400,000
Distributor Agreement, Purchase, Each year, Next Two Years			650,000
Lessor, Sales-type Lease, Assumptions and Judgments, Value of Underlying Asset, Amount		$ 180,000	$ 180,000
Property, Plant and Equipment, Useful Life (Year)			5 years
Distribution Agreement with AXP Distributor in China [Member] | Device Revenue [Member]
Expected Lease Revenue Per Quarter			$ 21,000

Note 3 - Summary of Significa_4

Note 3 - Summary of Significant Accounting Policies - Revenues (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net revenues	$ 3,158,000	$ 2,355,000	$ 6,876,000	$ 7,797,000
Device [Member] | AXP [Member]
Net revenues	2,310,000	1,169,000	3,670,000	4,112,000
Device [Member] | BioArchive [Member]
Net revenues	518,000	619,000	1,817,000	1,575,000
Device [Member] | CAR-TXpress [Member]
Net revenues	262,000	425,000	1,005,000	1,296,000
Device [Member] | Manual Disposables [Member]
Net revenues	55,000	100,000	300,000	499,000
Device [Member] | Other Subsegments [Member]
Net revenues	13,000	42,000	84,000	315,000
Device Revenue [Member]
Net revenues	2,662,000	1,932,000	5,190,000	6,494,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Net revenues	2,217,000	1,137,000	3,490,000	4,009,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Net revenues	221,000	337,000	652,000	675,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	160,000	332,000	702,000	1,035,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Net revenues	55,000	100,000	300,000	499,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	9,000	26,000	46,000	276,000
Service [Member]
Net revenues	400,000	336,000	1,413,000	1,050,000
Service [Member] | Device [Member] | AXP [Member]
Net revenues	72,000	32,000	159,000	103,000
Service [Member] | Device [Member] | BioArchive [Member]
Net revenues	297,000	282,000	1,165,000	900,000
Service [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	31,000	22,000	89,000	47,000
Other [Member]
Net revenues	96,000	87,000	273,000	253,000
Other [Member] | Device [Member] | CAR-TXpress [Member]
Net revenues	71,000	71,000	214,000	214,000
Other [Member] | Device [Member] | Other Subsegments [Member]
Net revenues	$ 4,000	$ 16,000	$ 38,000	$ 39,000

Note 3 - Summary of Significa_5

Note 3 - Summary of Significant Accounting Policies - Remaining Performance Obligations (Details)	Sep. 30, 2021USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 5,075,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	2,057,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	202,000
Device Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	1,410,000	[1]
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,406,000
[1]	Represents the minimum purchase requirements related to the Company AXP distributor in China

Note 3 - Summary of Significa_6

Note 3 - Summary of Significant Accounting Policies - Remaining Performance Obligations 2 (Details)	Sep. 30, 2021USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 5,075,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	6 months
Revenue, Remaining Performance Obligation, Amount	$ 455,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,935,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 1,435,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 529,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 721,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	$ 2,057,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	3 months
Revenue, Remaining Performance Obligation, Amount	$ 359,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 962,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 462,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 189,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 85,000
Clinical Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 202,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	3 months
Revenue, Remaining Performance Obligation, Amount	$ 3,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Clinical Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 160,000
Device Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,410,000	[1]
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	3 months	[1]
Revenue, Remaining Performance Obligation, Amount	$ 21,000	[1]
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year	[1]
Revenue, Remaining Performance Obligation, Amount	$ 674,000	[1]
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year	[1]
Revenue, Remaining Performance Obligation, Amount	$ 674,000	[1]
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year	[1]
Revenue, Remaining Performance Obligation, Amount	$ 41,000	[1]
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year	[1]
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,406,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	3 months
Revenue, Remaining Performance Obligation, Amount	$ 72,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Amount	$ 476,000
[1]	Represents the minimum purchase requirements related to the Company AXP distributor in China

Note 4 - Net Loss Per Share - A

Note 4 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020
Anti-dilutive securities (in shares)		8,091,084	8,996,967
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		7,071,241	6,988,334
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)			40,441
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]		69,853
Warrant, Other [Member]
Anti-dilutive securities (in shares)		653,248	1,006,190
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)		366,595	892,149
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants remained outstanding but unvested until they expired in February 2021.

Note 5 - Related Party Transa_3

Note 5 - Related Party Transactions (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Mar. 31, 2021	Jan. 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Apr. 28, 2020	Nov. 26, 2019	Dec. 31, 2018	Apr. 16, 2018	Mar. 31, 2017
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total			$ (1,792,000)	$ (2,609,000)	$ (8,994,000)	$ (13,862,000)
Assets, Current, Total			16,881,000		16,881,000		$ 15,298,000
Liabilities, Current, Total			$ 14,735,000		14,735,000		$ 6,143,000
Interest Paid, Excluding Capitalized Interest, Operating Activities					2,262,000	2,094,000
Amortization of Debt Discount (Premium)					$ 2,723,000	2,165,000
Boyalife Asset Holding II [Member] | Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage			22.00%		22.00%		22.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share)			$ 1.80		$ 1.80		$ 1.80			$ 1.80	$ 16.10
Boyalife Asset Holding II [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity												$ 10,000,000
Long-term Line of Credit, Total								$ 10,000,000
Debt Instrument, Interest Rate, Stated Percentage							22.00%
Interest Paid, Excluding Capitalized Interest, Operating Activities		$ 2,082,000
Amortization of Debt Discount (Premium)			$ 827,000	827,000	$ 2,482,000	2,103,000
Interest Expense, Debt, Excluding Amortization			562,000	$ 562,000	1,668,000	$ 1,519,000
Interest Payable			$ 1,668,000		$ 1,668,000		$ 2,082,000
ImmuneCyte and Shangai KDWinfo Technology Co. Ltd. [Member] | Boyalife’s Cellular Therapy Division [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	12,000,000
ImmuneCyte [Member] | Boyalife’s Cellular Therapy Division [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	500,000
ImmuneCyte [Member]
Equity Method Investment, Ownership Percentage			8.64%	18.79%	8.64%	18.79%			20.00%
Dilution Gain from Equity Method Investments					$ 262,000
Equity Method Investment Accumulated Gain Loss					(428,000)
Income (Loss) from Equity Method Investments, Total					0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total					750,000
Assets, Current, Total			$ 3,283,000		3,283,000
Liabilities, Current, Total			$ 2,970,000		$ 2,970,000
ImmuneCyte [Member] | HealthBanks Biotech [Member]
Equity Method Investment, Ownership Percentage				75.16%		75.16%			80.00%
ImmuneCyte [Member] | Private Institution [Member]
Equity Method Investment, Ownership Percentage				6.05%		6.05%

Note 5 - Related Party Transa_4

Note 5 - Related Party Transactions - Summarizes the Note (Details) - Boyalife Asset Holding II [Member] - Convertible Debt [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2018	Apr. 16, 2018
Debt Instrument, Maturity Date	Mar. 6, 2022	Mar. 6, 2022
State interest rate	22.00%	22.00%
Conversion price (in dollars per share)	$ 1.80	$ 1.80	$ 1.80	$ 16.10
Face value	$ 10,000,000	$ 10,000,000
Remaining debt discount	(1,583,000)	(4,065,000)
Carrying Value	$ 8,417,000	$ 5,935,000

Note 6 - Convertible Promisso_3

Note 6 - Convertible Promissory Note (Details Textual) - USD ($)	Jul. 23, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Amortization of Debt Discount (Premium)				$ 2,723,000	$ 2,165,000
Convertible Debt [Member] | The July 2019 Note [Member]
Debt Instrument, Face Amount	$ 1,000,000	$ 1,000,000		$ 1,000,000		$ 1,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.80		$ 1.80		$ 1.80
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90.00%
Debt Instrument, Interest Rate, Stated Percentage	24.00%	24.00%		24.00%		24.00%
Amortization of Debt Discount (Premium)		$ 80,000	$ 27,000	$ 241,000	107,000
Interest Expense, Debt, Total		$ 60,000	$ 60,000	$ 180,000	$ 180,000
Convertible Debt [Member] | The July 2019 Note [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 1.80
Convertible Debt [Member] | The July 2019 Note [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.50

Note 6 - Convertible Promisso_4

Note 6 - Convertible Promissory Note - Convertible Promissory Note (Details) - Convertible Debt [Member] - The July 2019 Note [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Jul. 23, 2019
Maturity Date	Jul. 31, 2022	Jul. 31, 2022
Stated Interest Rate	24.00%	24.00%	24.00%
Conversion Price (in dollars per share)	$ 1.80	$ 1.80
Face Value	$ 1,000,000	$ 1,000,000	$ 1,000,000
Remaining debt discount	(267,000)	(507,000)
Carrying Value	$ 733,000	$ 493,000

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Jan. 01, 2019
Operating Lease, Right-of-Use Asset	$ 614,000		$ 614,000		$ 730,000
Operating Lease, Payments	78,000	$ 76,000	231,000	$ 225,000
Operating Lease, Cost	$ 107,000	$ 135,000	$ 316,000	$ 343,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset						$ 966,000

Note 7 - Leases - Lease Informa

Note 7 - Leases - Lease Information (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Right-of-use operating lease assets, net	$ 614,000	$ 730,000
Non-current lease liability	$ 455,000	$ 604,000
Weighted average remaining lease term (Year)	2 years 8 months 12 days	3 years 4 months 24 days
Discount rate	22.00%	22.00%
Current Liabilities [Member]
Current lease liability (included in other current liabilities)	$ 193,000	$ 157,000

Note 7 - Leases - Maturities of

Note 7 - Leases - Maturities of Lease Liabilities (Details)	Sep. 30, 2021USD ($)
2021 (Remaining)	$ 78,000
2022	319,000
2023	328,000
2024	139,000
Total lease payments	864,000
Less: imputed interest	(217,000)
Present value of operating lease liabilities	$ 647,000

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2021	Jul. 13, 2020
Short Term Investment Minimum		$ 1,000,000
Minimum [Member]
Period Of Warranty On Products (Year)	1 year
Maximum [Member]
Period Of Warranty On Products (Year)	2 years

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Changes in Product Liability Included in Accrued Liabilities (Details)	9 Months Ended
	Sep. 30, 2021USD ($)
Balance	$ 154,000
Warranties issued during the period	53,000
Settlements made during the period	(140,000)
Balance	$ 67,000

Note 9 - Paycheck Protection _2

Note 9 - Paycheck Protection Program (Details Textual) - USD ($)	Apr. 21, 2020	Sep. 30, 2021
Gain (Loss) on Extinguishment of Debt, Total		$ 652,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total	$ 646,000
Gain (Loss) on Extinguishment of Debt, Total		$ 652,000

Note 10 - Employee Retention _2

Note 10 - Employee Retention Tax Credit (Details Textual)	9 Months Ended
	Sep. 30, 2021USD ($)
Employee Retention Tax Credit	$ 842,000

Note 11 - Stockholders' Equit_2

Note 11 - Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended		22 Months Ended
	May 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	May 19, 2020	Dec. 13, 2019
Proceeds from Issuance of Common Stock, Net					$ 6,832,000	$ 5,580,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares)					523,041
Share-based Payment Arrangement, Expense		$ 92,000		$ 234,000	$ 2,449,000	$ 615,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)					0
Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares)	490,000
Executive Officer [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Accelerated Cost			$ 2,008,000
At The Market Offering Agreement [Member]
Maximum Offering Price for Issuance of Common Stock								$ 15,280,313	$ 4,400,000
Stock Issued During Period, Shares, New Issues (in shares)					2,976,832		5,597,484
Proceeds from Issuance of Common Stock							$ 15,280,000
Shares Issued, Price Per Share (in dollars per share)		$ 2.73			$ 2.73		$ 2.73
Proceeds from Issuance of Common Stock, Net					$ 6,832,000		$ 14,568,000
Payments of Stock Issuance Costs					$ 224,000		$ 712,000

Note 11 - Stockholders' Equit_3

Note 11 - Stockholders' Equity - Stock-based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Stock-based compensation	$ 92,000	$ 234,000	$ 2,449,000	$ 615,000
Cost of Sales [Member]
Stock-based compensation	4,000	3,000	14,000	5,000
Selling, General and Administrative Expenses [Member]
Stock-based compensation	64,000	195,000	2,194,000	538,000
Research and Development Expense [Member]
Stock-based compensation	$ 24,000	$ 36,000	$ 241,000	$ 72,000

Note 11 - Stockholders' Equit_4

Note 11 - Stockholders' Equity - Option Activity for Stock Option Plans (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Outstanding, options (in shares)	889,636
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 8.57
Cancelled / Forfeited, options (in shares)	523,041
Outstanding, options (in shares)	366,595
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 11.86
Outstanding, weighted average remaining contractual life, options (Year)	7 years 1 month 6 days
Vested and expected to vest, options (in shares)	331,128
Vested and expected to vest, weighted average exercise price, options (in dollars per share) | $ / shares	$ 12.36
Vested and expected to vest, weighted average remaining contractual life, options (Year)	6 years 10 months 24 days
Exercisable, options (in shares)	244,245
Exercisable, weighted average exercise price, options (in dollars per share) | $ / shares	$ 13.97
Exercisable, weighted average remaining contractual life, options (Year)	7 years

Note 11 - Stockholders' Equit_5

Note 11 - Stockholders' Equity - Warrant Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Outstanding (in shares)	1,116,484
Outstanding, weighted average exercise price (in dollars per share)	$ 37.27
Outstanding, Weighted Average Remaining Contract Term (Year)	1 year 8 months 12 days	5 months 26 days
Warrants expired (in shares)	463,236
Outstanding (in shares)	653,248	1,116,484
Outstanding, weighted average exercise price (in dollars per share)	$ 6.97	$ 37.27
Exercisable (in shares)	653,248
Exercisable, weighted average exercise price (in dollars per share)	$ 6.97
Exercisable, Weighted Average Remaining Contract Term (Year)	1 year 8 months 12 days

Note 12 - Major Customers and_2

Note 12 - Major Customers and Accounts Receivable (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Revenue Benchmark [Member] | Customer 1 [Member]
Concentration Risk, Percentage	42.00%	20.00%	19.00%	12.00%
Revenue Benchmark [Member] | Customer 2 [Member]
Concentration Risk, Percentage	24.00%	22.00%	17.00%	27.00%
Revenue Benchmark [Member] | Customer 3 [Member]
Concentration Risk, Percentage	0.00%	10.00%	10.00%	12.00%
Accounts Receivable [Member]
Number of Major Customers			2		3
Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage			67.00%
Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage					72.00%